Emerging clinical setting of direct oral anticoagulants: atherothrombotic events prevention
| Autor: | Domenico Gabrielli, Fabiana Lucà, Michele Massimo Gulizia, Furio Colivicchi, Stefania Angela Di Fusco |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Rivaroxaban Atherothrombotic disease business.industry Atherosclerotic disease Administration Oral Anticoagulants Thrombosis General Medicine Coronary Artery Disease Vitamin k Peripheral Arterial Disease Treatment Outcome Coagulation Risk Factors Medicine Humans Cardiology and Cardiovascular Medicine business Intensive care medicine Blood Coagulation medicine.drug |
| Zdroj: | Journal of cardiovascular medicine (Hagerstown, Md.). 21(1) |
| ISSN: | 1558-2035 |
| Popis: | Despite substantial progress in the treatment of atherosclerotic disease a non-negligible rate of acute atherothrombotic events persists. Evidence suggesting a safer profile of direct oral anticoagulants (DOACs) compared with vitamin K antagonists and the involvement of coagulation in the atherosclerotic process has led to exploration of the role of DOACs in the prevention of atherothrombotic events. In this review, we discuss the findings of recent studies on DOACs, particularly rivaroxaban, in atherothrombotic disease which represents a new clinical setting for oral anticoagulants. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|